Princeton-based Made Scientific, a cell therapy contract development and manufacturing organization (CDMO), and Hemogenyx Pharmaceuticals, a New York-based clinical-stage biopharmaceutical company, on Monday announced a new partnership to advance HG-CT-1, a CAR-T cell therapy for the treatment of relapsed/refractory acute myeloid leukemia (r/r AML).
Under this agreement, Hemogenyx will use Made Scientific’s expertise and its GMP-compliant facilities in Newark and Princeton for the technology transfer and manufacturing of HG-CT-1. The partnership is a crucial step in advancing Hemogenyx’s ongoing Phase I clinical trial for adult patients and could support the future inclusion of a pediatric cohort.
Hemogenyx Pharmaceuticals’ CEO and Co-Founder, Dr. Vladislav Sandler, emphasized the importance of a trusted CDMO for the success of their lead therapy. He stated that Made Scientific’s manufacturing expertise will be instrumental in driving the continued progress of this “potentially breakthrough therapy.”
Early clinical data from the trial has shown promising results, building confidence in both the therapy’s safety and potential efficacy.
Syed Husain, chairman & CEO of Made Scientific, commented that the collaboration reflects his company’s commitment to advancing “next-generation cell therapies that address urgent, unmet medical needs.” He added that Made Scientific is proud to support Hemogenyx in its Phase I clinical trial with its integrated solutions and experienced team.
The partnership underscores both companies’ dedication to developing innovative treatments for life-threatening diseases, with Made Scientific focusing on its mission to “Defy Limits. Deliver Results.”
More from BINJE:
